Dr. Reddy’s: Base Growth Holds as Semaglutide Supply Pressures Margins

Transcript intelligence

What changed

Compared with the prior quarter, the focus shifted from expected semaglutide and biosimilar expansion to the effect of semaglutide API and supply problems, a lower FY27 capex plan and a Form 483 with seven observations. Management nevertheless maintained its roughly 20% FY27 EBITDA margin guidance and emphasized a strong pipeline and second-half execution.

Guidance delta

Management maintained guidance of roughly 20% EBITDA margin for FY27 and expects margins to improve to the high teens excluding the semaglutide impact.

Key takeaways

• Underlying base business growth remained healthy across key regions despite a reported Q1 FY27 revenue decline.
• Semaglutide supply and API-quality issues reduced near-term performance; management expects supply to resume by November 2026.
• Management maintained its roughly 20% FY27 EBITDA margin guidance and cited productivity measures.
• New launches and the pipeline, including bosutinib, nintedanib, oral semaglutide and abatacept, support the growth case.
• Lower FY27 capex reflects a more disciplined investment pace, while cash remains available for inorganic opportunities.

Management priorities

• Resolve semaglutide API and supply constraints and resume commercial supplies.
• Advance complex generic, semaglutide and biosimilar launches, including abatacept.
• Scale peptide and biosimilar facilities while pursuing selective inorganic growth.